News
Alvotech (NASDAQ:ALVO) and Dr. Reddy’s Laboratories (NYSE:RDY) have entered into a collaboration and license agreement to ...
Procter & Gamble said Thursday it plans to cut 7,000 jobs, about 15% of its workforce, over two years. The company said it's ...
U.S. aid cuts could jeopardize the supply of donated drugs that are hailed for their effectiveness in combating neglected ...
An analysis of the CALLA study shows that ctDNA is detected an average of 5.5 months before radiographic progression.
Merck & Co. Inc. closed 42.70% short of its 52-week high of $134.63, which the company reached on June 25th.
However, beneath this success lies a growing concern: the sustainability of this growth trajectory, particularly as ...
3d
Medpage Today on MSNAdjuvant Cemiplimab Improves Disease-Free Survival in High-Risk Cutaneous SCCCHICAGO -- Adjuvant cemiplimab (Libtayo) significantly improved disease-free survival (DFS) compared with placebo in patients ...
Dr. Reddy's Laboratories and Alvotech have partnered to co-develop, manufacture, and commercialize a biosimilar of Keytruda ...
3don MSN
Merck & Co., Inc. (NYSE: MRK) has explored a potential acquisition of Swiss biotech firm MoonLake Immunotherapeutics in a ...
Barreling toward the loss of exclusivity on its blockbuster oncology therapy Keytruda, Merck & Co. has reportedly offered $3 ...
Dr. Reddy's and Alvotech collaborate to develop biosimilar to Keytruda, enhancing oncology capabilities and global reach.
Merck reportedly offered over $3 billion for MoonLake Immunotherapeutics, targeting its late-stage inflammatory drug as it ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results